Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
61actual
Sites
17
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-27 | actual | When the study began enrolling |
| Primary completion | 2025-08-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-25 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-01 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-17 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Interventions
- Drug: INCAGN02385
- Drug: INCAGN02390
- Drug: INCMGA00012.
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
measured up to 1148 days
Phase 1: Number of Participants With Any ≥Grade 3 TEAE
measured up to 1148 days
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-03-02 · 1.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-05-23 · 641 KB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed